Literature DB >> 30212638

UK newspaper reporting of the NHS cancer drugs fund, 2010 to 2015: a retrospective media analysis.

Grant Lewison1,2, Ajay Aggarwal1,3, Philip Roe2, Henrik Møller1, Charlotte Chamberlain4, Richard Sullivan1.   

Abstract

Objective We wished to explore how UK national newspapers had covered the creation and operation of the Cancer Drugs Fund from 2010 to 2015. This was introduced to provide cancer patients in England with access to drugs not appraised or approved by the National Institute for health and Care Excellence. Design We sought stories in nine newspapers from the Factiva database, and copied their salient details to a spreadsheet. They were categorised by whether they were supportive or critical of the Cancer Drugs Fund and their main arguments, which drugs they mentioned and for which cancers. Settings Not applicable Participants Not applicable Main outcome results Press coverage was mainly very positive, arguing for the Cancer Drugs Fund's extension to Scotland and Wales, and a bigger budget, but neglecting the lack of patient benefit and the severe side effects that sometimes occurred. Leading this support was the Daily Mail, whose influence (measured by the product of number of stories and the paper's circulation) was almost greater than that of the other newspapers combined. Results Press coverage was mainly very positive, arguing for the Cancer Drugs Fund's extension to Scotland and Wales, and a bigger budget, but neglecting the lack of patient benefits and the severe side effects that sometimes occurred. Leading this support was the Daily Mail, whose influence (measured by the product of number of stories and the paper's circulation) was almost greater than that of the other newspapers combined. Conclusions Although there was some critical analysis of the Cancer Drugs Fund, our analysis shows that most press coverage was largely positive and unrepresentative in comparison with the lack of overall benefits to patients and society. It is likely that it contributed to the Cancer Drugs Fund's continuation despite mounting evidence of its ineffectiveness.

Entities:  

Keywords:  Effectiveness of care; chemotherapy; drugs and medicines; medicines regulation; oncology

Mesh:

Substances:

Year:  2018        PMID: 30212638      PMCID: PMC6194957          DOI: 10.1177/0141076818796802

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  10 in total

Review 1.  Death and illness as depicted in the media.

Authors:  J M L Williamson; C I Skinner; D B Hocken
Journal:  Int J Clin Pract       Date:  2011-05       Impact factor: 2.503

2.  The State of Lung Cancer Research: A Global Analysis.

Authors:  Ajay Aggarwal; Grant Lewison; Saliha Idir; Matthew Peters; Carolyn Aldige; Win Boerckel; Peter Boyle; Edward L Trimble; Philip Roe; Tariq Sethi; Jesme Fox; Richard Sullivan
Journal:  J Thorac Oncol       Date:  2016-03-21       Impact factor: 15.609

3.  Cancer and the media: how does the news report on treatment and outcomes?

Authors:  Jessica Fishman; Thomas Ten Have; David Casarett
Journal:  Arch Intern Med       Date:  2010-03-16

Review 4.  Nanotechnologies for the treatment of colon cancer: From old drugs to new hope.

Authors:  Larissa Kotelevets; Eric Chastre; Didier Desmaële; Patrick Couvreur
Journal:  Int J Pharm       Date:  2016-11-30       Impact factor: 5.875

Review 5.  The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.

Authors:  Graeme Morgan; Robyn Ward; Michael Barton
Journal:  Clin Oncol (R Coll Radiol)       Date:  2004-12       Impact factor: 4.126

6.  Trends in the global funding and activity of cancer research.

Authors:  Seth Eckhouse; Grant Lewison; Richard Sullivan
Journal:  Mol Oncol       Date:  2008-03-27       Impact factor: 6.603

7.  International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes.

Authors:  Filippo de Marinis; Emilio Bria; Fortunato Ciardiello; Lucio Crinò; Jean Yves Douillard; Frank Griesinger; Diether Lambrechts; Maurice Perol; Suresh S Ramalingam; Egbert F Smit; Cesare Gridelli
Journal:  J Thorac Oncol       Date:  2016-04-05       Impact factor: 15.609

8.  Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.

Authors:  Filippo Pietrantonio; Chiara Cremolini; Giuseppe Aprile; Sara Lonardi; Armando Orlandi; Alessia Mennitto; Rosa Berenato; Carlotta Antoniotti; Mariaelena Casagrande; Valentina Marsico; Federica Marmorino; Giovanni Gerardo Cardellino; Francesca Bergamo; Gianluca Tomasello; Vincenzo Formica; Raffaella Longarini; Elisa Giommoni; Marta Caporale; Maria Di Bartolomeo; Fotios Loupakis; Filippo de Braud
Journal:  Oncologist       Date:  2015-10-07

Review 9.  Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.

Authors:  A Aggarwal; T Fojo; C Chamberlain; C Davis; R Sullivan
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

10.  How do the media report cancer research? A study of the UK's BBC website.

Authors:  G Lewison; S Tootell; P Roe; R Sullivan
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

  10 in total
  4 in total

1.  The seductive hope of cancer therapies.

Authors:  Kamran Abbasi
Journal:  J R Soc Med       Date:  2018-10       Impact factor: 5.344

2.  NHS cancer drugs fund.

Authors:  Heather Goodare
Journal:  J R Soc Med       Date:  2019-02       Impact factor: 5.344

3.  Impact of reduced working hours on the NHS.

Authors:  Terence English
Journal:  J R Soc Med       Date:  2019-02       Impact factor: 5.344

4.  Relationships between types of UK national newspapers, illness classification, and stigmatising coverage of mental disorders.

Authors:  Yan Li; Rosanna Hildersley; Grace W K Ho; Laura Potts; Claire Henderson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2021-01-22       Impact factor: 4.328

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.